AR052888A1 - Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacion - Google Patents
Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacionInfo
- Publication number
- AR052888A1 AR052888A1 ARP060100266A ARP060100266A AR052888A1 AR 052888 A1 AR052888 A1 AR 052888A1 AR P060100266 A ARP060100266 A AR P060100266A AR P060100266 A ARP060100266 A AR P060100266A AR 052888 A1 AR052888 A1 AR 052888A1
- Authority
- AR
- Argentina
- Prior art keywords
- ppar
- formulation
- agonist
- prepare
- package
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 5
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108010028924 PPAR alpha Proteins 0.000 abstract 5
- 102000023984 PPAR alpha Human genes 0.000 abstract 5
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 abstract 1
- 108010015181 PPAR delta Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de agonista alfa de PPAR para preparar una formulacion farmacéutica de formula (1), util para tratar una enfermedad o condicion, que comprende la administracion del agonista alfa de PPAR de acuerdo con una programacion de la dosificacion, que comprende un período de dosificacion menor que una dosis diaria. El agonista alfa de PPAR es al menos dos veces más selectivo para PPAR alfa de lo que lo es para PPAR gama, PPAR delta y PPAR gama/delta. La programacion de la dosificacion comprende al menos un día, o siete días en los que no hay administracion o frecuencia no mayor que una vez por semana, bisemanalmente o una vez al mes. El agonista alfa de PPAR es el ácido 2-[4-[3-[2,5-dihidro-1-[(4-metilfenil)metil]-5-oxo-1H-1,2,4-triazol-3- il]propil]fenoxi]-2-metil- propanoico o una sal farmacéutica del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64790305P | 2005-01-28 | 2005-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052888A1 true AR052888A1 (es) | 2007-04-11 |
Family
ID=36616964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100266A AR052888A1 (es) | 2005-01-28 | 2006-01-24 | Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacion |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080207716A1 (es) |
| EP (1) | EP1850845A2 (es) |
| JP (1) | JP2008528603A (es) |
| CN (1) | CN101106988A (es) |
| AR (1) | AR052888A1 (es) |
| BR (1) | BRPI0606805A2 (es) |
| CA (1) | CA2595770A1 (es) |
| DO (1) | DOP2006000018A (es) |
| MX (1) | MX2007009142A (es) |
| PE (1) | PE20061041A1 (es) |
| TW (1) | TW200640453A (es) |
| WO (1) | WO2006083645A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2688187C (en) | 2007-05-07 | 2016-10-11 | Merck & Co., Inc. | Method of treament using fused aromatic compounds having anti-diabetic activity |
| WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
| WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| JP6404230B2 (ja) | 2012-12-20 | 2018-10-10 | インセプション ２、 インコーポレイテッド | トリアゾロン化合物およびその使用 |
| EA201690230A1 (ru) | 2013-09-06 | 2016-07-29 | Инсепшн 2, Инк. | Соединения триазолона и их применения |
| WO2017044551A1 (en) * | 2015-09-11 | 2017-03-16 | Mitobridge, Inc. | Ppar-alpha agonists for treating mitochondrial diseases |
| JP7229772B2 (ja) | 2016-04-22 | 2023-02-28 | ジェイシー（ウーシー） カンパニー，インコーポレーテッド | イソチオシアネート系化合物の使用 |
| WO2018016596A1 (ja) * | 2016-07-20 | 2018-01-25 | 国立大学法人東北大学 | ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA82048C2 (uk) * | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
| SE0101981D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| ATE319449T1 (de) * | 2001-12-21 | 2006-03-15 | Smithkline Beecham Corp | Dosierschema für ppar-gamma-aktivatoren |
-
2006
- 2006-01-24 PE PE2006000107A patent/PE20061041A1/es not_active Application Discontinuation
- 2006-01-24 DO DO2006000018A patent/DOP2006000018A/es unknown
- 2006-01-24 AR ARP060100266A patent/AR052888A1/es unknown
- 2006-01-24 TW TW095102645A patent/TW200640453A/zh unknown
- 2006-01-25 CN CNA2006800031037A patent/CN101106988A/zh active Pending
- 2006-01-25 MX MX2007009142A patent/MX2007009142A/es not_active Application Discontinuation
- 2006-01-25 CA CA002595770A patent/CA2595770A1/en not_active Abandoned
- 2006-01-25 US US11/814,487 patent/US20080207716A1/en not_active Abandoned
- 2006-01-25 WO PCT/US2006/002606 patent/WO2006083645A2/en not_active Ceased
- 2006-01-25 EP EP06719460A patent/EP1850845A2/en not_active Withdrawn
- 2006-01-25 BR BRPI0606805-7A patent/BRPI0606805A2/pt not_active IP Right Cessation
- 2006-01-25 JP JP2007553198A patent/JP2008528603A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2595770A1 (en) | 2006-08-10 |
| BRPI0606805A2 (pt) | 2010-02-09 |
| WO2006083645A2 (en) | 2006-08-10 |
| WO2006083645A3 (en) | 2006-12-28 |
| MX2007009142A (es) | 2007-11-21 |
| US20080207716A1 (en) | 2008-08-28 |
| DOP2006000018A (es) | 2006-07-15 |
| CN101106988A (zh) | 2008-01-16 |
| TW200640453A (en) | 2006-12-01 |
| PE20061041A1 (es) | 2006-10-12 |
| JP2008528603A (ja) | 2008-07-31 |
| EP1850845A2 (en) | 2007-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2233282T3 (es) | Agentes antiobesidad tiromimeticos. | |
| AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
| Vessal et al. | Silymarin and milk thistle extract may prevent the progression of diabetic nephropathy in streptozotocin-induced diabetic rats | |
| ES2742815T3 (es) | Uso antiparasitario de compuestos de isoxazolina | |
| RU2011144438A (ru) | Мочевинные активаторы глюкокиназы | |
| MA28921B1 (fr) | Derive heterocyclique azote et medicament le contenant en tant que principe actif | |
| AR054261A1 (es) | Sales fisiologicamente compatibles de ester etilico del acido 3-(2-{(4-(hexiloxicarbonilamino-imino-metil )-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propionico, composiciones farmaceuticas que las contienen y su uso en la preparacion de un medicamento para la profil | |
| BRPI0615150A2 (pt) | agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo | |
| AR052888A1 (es) | Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacion | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| BRPI0517701A (pt) | uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus | |
| AR112137A1 (es) | Preparación sólida para administración oral que comprende cariprazina | |
| BRPI0720500A8 (pt) | Preparação líquida transdérmica | |
| RU2016114098A (ru) | Новое производное аналога инсулина | |
| BR112012006841B8 (pt) | combinação de composto ativo, seus usos e método para curativamente ou preventivamente controlar os fungos fitopatogênicos e/ou microrganismos e/ou pragas de plantas ou safras | |
| AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
| JP2006527234A5 (es) | ||
| Bang et al. | Enzogenol improves diabetes-related metabolic change in C57BL/KsJ-db/db mice, a model of type 2 diabetes mellitus | |
| AR054595A1 (es) | Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis | |
| AR031078A1 (es) | Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima. | |
| Jones | Conceptual model for using imidazoline derivative solutions in pulpal management | |
| Kelly et al. | Long term augmentation with T3 in refractory major depression | |
| US20020147206A1 (en) | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | |
| Guimaraes et al. | Effects of induced diabetes and the administration of aminoguanidine in the biomechanical retention of implants: a study in rats | |
| AR083893A1 (es) | Uso de una composicion farmaceutica que comprende (s) (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol para preparar un medicamento topico de utilidad en la reduccion de la presion intraocular y articulo de manufactura correspondiente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |